.Attribute Medicine, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medication conjugate (ADC) tisotumab vedotin resulted in boosted progression-free and overall survival, triggering FDA commendation and a new therapy alternative for people.